Under construction – not a live service
Sign in
Taking people in United StatesPhase 2

Home Brain Stimulation Device Tested for Fatigue After Stroke

Tests a mild brain stimulation device for fatigue in adults recovering from stroke.

Plain-language title generated from the registry record
Registry title: Transcranial Direct Current Stimulation for Post-stroke Fatigue

Key facts

Where
New York, United StatesSee the site
Phase
Phase 2

Where in United States

  • Weill Cornell Medicine, 525 E. 68th St, Baker Pavilion, F-2106New York, United StatesTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Weill Medical College of Cornell University
Trial code
NCT05816603
Record updated
27 February 2026
Original description
The investigators hypothesize that delivery of anodal tDCS to the left frontal head region will reduce fatigue severity following stroke.Read full original descriptionShow less

Home-based Post-stroke Fatigue Treatment Using Transcranial Direct Current Stimulation (tDCS)

The investigators hypothesize that delivery of anodal tDCS to the left frontal head region will reduce fatigue severity following stroke.

Inclusion: Male or female patients aged >18 years; Greater than 3 months from first hemorrhagic or ischemic stroke (subacute to chronic), confirmed through neuroimaging (CT or MRI); Fatigue severity score average >4 (severe fatigue); Willingness to remain stable on pharmacologic therapy through the duration of the study; Availability of a caregiver, family member, or friend to be present during the administration of the tDCS intervention.

Exclusion: History of seizure; History of moderate to severe traumatic brain injury; A score of less than 21 on the MoCA suggesting major neurocognitive disorder; Signs of skin rash, infection, or laceration in the supraorbital region where the tDCS will be applied; Other major neurological, medical, or psychiatric illnesses that could confound results in the opinion of the site investigator; Metal in the head (except mouth) or implanted cranial or thoracic devices (i.e. pacemaker, DBS stimulator); A score of 10 or more on the PHQ-9 or GAD-7 scale, suggestive of moderate to severe depression/anxiety; Inability to provide informed consent.

ClinicalTrials.gov NCT05816603